Ecco perchè sui "vaccini" è stato imposto il segreto militare. A quattro anni di distanza c’è ancora chi pensa che Pfizer e Moderna (che fino ad allora non avevano MAI commercializzato nulla) siano riusciti a mettere a punto vaccini in poche settimane, mentre colossi come Sanofi restavano con le mani in mano… Robert Kennedy Jr. che sa benissimo di cosa sta parlando: “I vaccini NON sono stati sviluppati da Moderna-Pfizer... ma dal NIH. I brevetti sono detenuti dal NIH. Sono stati creati da appaltatori militari. Pfizer e Moderna sono state pagate come se provenissero dall’industria farmaceutica. Erano un progetto militare..." This is why "vaccines" were subjected to military secrecy. Four years later, there are still those who think that Pfizer and Moderna (who had NEVER marketed anything until then) managed to develop vaccines in a few weeks, while giants like Sanofi sat idle… Robert Kennedy Jr. who knows very well what he is talking about: "The vaccines were NOT developed by Moderna-Pfizer... but by the NIH. The patents are held by the NIH. They were created by military contractors. Pfizer and Moderna were paid as if they came from the pharmaceutical industry. They were a military project..." Fonte: https://x.com/itsmeback_/status/1844269165235913106?t=ti1J3wj_KKVg303CoZDhhg&s=19

Oncology Market Rising Trends, Demand and Future Scope 2024 to 2031 Leading market research firm SkyQuest Technology Group recently released a study titled 'Oncology Market Global Size, Share, Growth, Industry Trends, Opportunity and Forecast 2024-2031,' This study Oncology report offers a thorough analysis of the market, as well as competitor and geographical analysis and a focus on the most recent technological developments. The research study on the Oncology Market extensively demonstrates existing and upcoming opportunities, profitability, revenue growth rates, pricing, and scenarios for recent industry analysis. The research analysis on the global Oncology Market report 2024 offers a close watch on top industry rivals along with briefings on their company profiles, strategical surveys, micro as well as macro industry trends, futuristic scenarios, analysis of pricing structure, and an all-encompassing overview of the Oncology Market circumstances in the forecast period between 2024 and 2031. The global Oncology Market is a dynamic and rapidly evolving sector, encompassing the development, production, and distribution. This market is essential for improving global market and driving economic growth through innovation and industry advancements. Market Growth The Oncology Market has experienced robust growth over the past decade and is projected to continue expanding. Oncology Market size was valued at USD 286.04 billion in 2022 and is poised to grow from USD 309.3 billion in 2023 to USD 581.25 billion by 2031, growing at a CAGR of 8.2% in the forecast period (2024-2031). This growth is driven by several factors, including an aging global population, increasing prevalence of advancements in technology, and rising global expenditure. Chance to get a free sample @ https://www.skyquestt.com/sample-request/oncology-market Detailed Segmentation and Classification of the report (Market Size and Forecast - 2031, Y-o-Y growth rate, and CAGR): The Oncology Market can be segmented based on several factors, including product type, application, end-user, and distribution channel. Understanding these segments is crucial for companies looking to target specific markets and tailor their offerings to meet consumer needs. Cancer Diagnostics & Treatment Cancer Diagnostics {Tumor Biomarker Test, Imaging, Biopsy, Liquid Biopsy, Immunohistochemistry, In Situ Hybridization}, Cancer Treatment {Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy} Cancer Type Lung Cancer, Prostate Cancer, Colon & Rectal Cancer, Gastric Cancer, Esophageal Cancer, Liver Cancer, Breast Cancer End-Use Hospitals, Diagnostic Laboratories, Diagnostic Imaging Centers, Academia, Specialty Clinics Get your customized report @ https://www.skyquestt.com/speak-with-analyst/oncology-market Following are the players analyzed in the report: Roche Holding AG Novartis International AG Bristol-Myers Squibb Company Pfizer Inc. Merck & Co., Inc. AstraZeneca PLC Johnson & Johnson Sanofi S.A. Takeda Pharmaceutical Company Limited Amgen Inc. AbbVie Inc. Eli Lilly and Company Gilead Sciences, Inc. Celgene Corporation (a subsidiary of Bristol-Myers Squibb Company) Bayer AG Biogen Inc. Daiichi Sankyo Company, Limited Astellas Pharma Inc. Eisai Co., Ltd. Teva Pharmaceutical Industries Ltd. Regional Analysis 1. North America: - The United States and Canada dominate the North American Oncology Market. The U.S. is the largest market globally, driven by advanced global infrastructure, high R&D investments, and significant Oncology consumption. 2. Europe: - Europe is a significant player, with major Oncology Markets in Germany, France, and the United Kingdom. The region benefits from strong regulatory frameworks, high industry standards, and a robust R&D sector. 3. Asia-Pacific: - This region is experiencing rapid growth, with countries like China and India leading the charge. Factors such as increasing industry access, growing middle-class populations, and expanding Oncology manufacturing capabilities contribute to this growth. 4. Latin America: - Brazil and Mexico are key markets in Latin America. Growth in this region is driven by rising industry needs, increasing investments in industry infrastructure, and a growing demand for affordable medications. 5. Middle East and Africa: - The Oncology Market in this region is expanding due to rising market spending, increased prevalence of diseases, and improvements in Market infrastructure, although the market is relatively smaller compared to other regions. Future Outlook The Oncology Market is poised for continued growth driven by technological advancements, expanding global market access, and increasing global industry needs. As the industry adapts to evolving challenges and seizes emerging opportunities, it is likely to see ongoing innovation and expansion, contributing significantly to global health and economic development. Buy your full report: https://www.skyquestt.com/buy-now/oncology-market

Video censurato da Facebook e pubblicato su Napebook.com - il Social contro la censura. I soldi delle case farmaceutiche a chi decide sui vaccini: SItI (società italiana di igiene) FIMMG (Federazione italiana dei medici di famiglia) fimp (federazione italiana medici pediatri) e SIP (Società italiana di Pediatria). MASSIMA CONDIVISIONE!!! #collusioneordinipediatrici #societaitalianpediatria #confliettodiinteressi #merck #gsk #sanofi #pfizer

🔴 CORVELVA: ECCO COSA ABBIAMO TROVATO NEI VACCINI PEDIATRICI. In collegamento con il canale televisivo Telecolor, Mattia Marchi - presidente dall’Associazione Corvelva, Coordinamento Regionale Veneto per la Libertà delle Vaccinazioni - spiega la recente decisione del GIP del tribunale di Roma di creare un gruppo interforze, NAS e/o RIS, che esamini i risultati da presentati da Corvelva nel luglio del 2018 (ne abbiamo parlato qui). Riepilogando quanto emerso dalle analisi effettuate da Corvelva sui vaccini pediatrici, Marchi ha ricordato che: "Nel vaccino Priorix Tetra della Sanofi Pasteur non abbiamo trovato la rosolia [...] Mancava la polio nell'esavalente [...] Nel Priorix Tetra abbiamo trovato un quantitativo di DNA enorme, praticamente il 95% del quantitativo genetico nel vaccino è DNA umano, ma non solo: abbiamo trovato dei virus che non ci devono essere." #telecolor #vaccinipediatrici #Corvelva